AF
STRO icon

Amalgamated Financial’s Sutro Biopharma STRO Stock Holding History

Amalgamated Financial’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$44K Buy
+538
New +$51.2K ﹤0.01% 2486

Other funds holding STRO

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Amalgamated Financial's STRO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Sutro Biopharma (STRO) in Q1 2022: 538 shares worth $44K. The stake represents ﹤0.01% of the portfolio and ranks #2486 among its holdings.

114 funds tracked by Wall St. Rank hold STRO as of Q1 2022.

  • Amalgamated Financial held 538 shares of Sutro Biopharma worth $44K as of Q1 2022.
  • Sutro Biopharma was a new Amalgamated Financial position in Q1 2022.
  • Sutro Biopharma made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2486 holding.
  • 114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.